DDInter1247 DDInter927
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Moxifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Moxifloxacin {u} (Compound) binds {v} (Gene) TOP2A
Moxifloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Moxifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Moxifloxacin {u} (Compound) causes {v} (Side Effect) Oedema
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium acetate
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Eribulin
Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Moxifloxacin (Compound) binds TOP2A (Gene)
Moxifloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Moxifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Moxifloxacin (Compound) causes Oedema (Side Effect)
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium acetate
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Moxifloxacin may lead to a major life threatening interaction when taken with Eribulin